Anticholinergic Inhaler Medicines Risky for COPD Patients

by Kathy Jones on  May 24, 2011 at 10:54 PM General Health News
RSS Email Print This Page Comment bookmark
Font : A-A+

Opting for anticholinergic inhaler medicines could prove to be risky for patients with Chronic Obstructive Pulmonary Disease (COPD) with a new study suggesting that the medicines increase the risk of the patients suffering from emergency situations.
 Anticholinergic Inhaler Medicines Risky for COPD Patients
Anticholinergic Inhaler Medicines Risky for COPD Patients

Currently two types of treatments are used for COPD, a daily dose of Spiriva prescription medication and salmeterol HFA-MDI inhaler though the later is not approved in the United States.

According to the study, which has been published in the Archives of Internal Medicines; using anticholinergic medicines such as Atrovent and Spiriva increase the risk of acute urinary retention by almost 40 percent.

"The thing is that often people don't associate (the inhaled drugs) with a problem peeing. Not only does the patient not necessarily make that connection, but I think clinicians don't make the connection because there's a belief, not necessarily rightly, that the drugs aren't systemically absorbed", lead researcher Anne Stephenson said.




Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Pneumoconiosis Pulmonary Arterial Hypertension Chronic Obstructive Pulmonary Disease Emphysema Pneumonectomy Chronic Bronchitis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive